GSK’s Juluca gets European Medicines Agency approval for HIV therapy
Date: 2018-03-24   Author: Dhananjay Punekar  Category: #news

GSK’s Juluca gets European Medicines Agency approval for HIV therapy

European Medicines Agency, an EU authority that evaluates medicinal products, has approved GlaxoSmithKline’s two-drug treatment for HIV (human immunodeficiency virus), that causes AIDS (Acquired Immune Deficiency Syndrome). Reportedly, the board constituted for evaluating the human use of medicinal product supported the application of the two-drug regimen.

Juluca, a new HIV drug therapy, is a fixed dosage tablet combining two previously approved medicines, rilpivirine & dolutegravir, and is available for the patients on a stable drug treatment for nearly half of the year.

As per reliable reports, Juluca has been produced by GSK’s subsidiary ViiV Healthcare, which has a small stake owned by Shionogi and Pfizer. ViiV’s integrase inhibitor medicine dolutegravir is a part of GSK’s old triple-drug treatment that is used to control the spread of HIV in the human body.

Earlier, in the last quarter of 2017, U.S Food and Drug Administration (FDA) had approved the two-drug regimen of GSK. The CHMP (Committee for Medicinal Products for Human Use) approval is likely to facilitate Juluca’s approval by the European Commission, which is expected to come by the second quarter of this year. 

According to U.S. FDA, Juluca’s safety & efficiency in the adult HIV patients were assessed in two clinical tests in which 1,024 patients, whose HIV was suppressed due to the existing anti-HIV drug therapy, participated. Some of the patients were asked to either continue with the anti-HIV drug treatment or switch to Juluca’s two-drug therapy.

Reportedly, FDA derived the outcomes from the clinical trials on both the patients treated with GSK’s Juluca drug as well as the ones receiving anti-drug treatment. The regulator found that GSK’s two drug therapy had proved more effective in treating the HIV virus in the patients as compared to those who were treated with anti-HIV medicines.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

UK court of appeal rules Heathrow third runaway expansion plan illegal
Author: Saipriya Iyer

Heathrow airport’s third runway expansion plan has recently been declared as illegal by the UK appeals court on environmental grounds. The Paris climate agreement to mitigate greenhouse gas emission has been considered in the ruling, which h...


Neurostimulation Devices Market | Industry Developments, Outlook, Current Trends by 2025
Author: Rahul Varpe

The American Neurological Association says that neurological diseases affect more than 100 million American people each year. Reports suggest that North America neurostimulation devices market size is projected to depict a robust CAGR of over 13.5...


Antidiabetics Market | Regional Landscape, Production, Sales & Consumption Status and Prospects 2019-2025
Author: Rahul Varpe

Global Antidiabetics Market value is set to achieve a significant CAGR from 2019 to 2025, as per the new research report. With the exponentially growing population and the prevalence of a sedentary lifestyle, a significant rise in the patient pool...